Sofgen Pharma (PRCWF) director Bernal Jaramillo submits initial Form 3

Rhea-AI Filing Summary

Sofgen Pharma S.A. director Daniel Augusto Bernal Jaramillo filed an initial Form 3, which is a mandatory disclosure of insider status at the company. The filing reports no transactions or derivative positions, serving only to register his status as a reporting person.

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Bernal Jaramillo Daniel Augusto

(Last) (First) (Middle)

11600 MIRAMAR PARKWAY, SUITE 300

(Street)

MIRAMAR FLORIDA 33025

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Sofgen Pharma S.A. [ PROC ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

See Exhibit 24 - Power of Attorney.

No securities are beneficially owned.

	/s/ Freddy Andres Lozano Reyes, attorney-in-fact	03/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does the Sofgen Pharma (PRCWF) Form 3 filing report?

The Form 3 filing for Sofgen Pharma reports that Daniel Augusto Bernal Jaramillo is a director and thus an insider. It shows no stock transactions or derivative positions, serving only as his initial ownership disclosure as a reporting person.

Who is the reporting person in the Sofgen Pharma PRCWF Form 3?

The reporting person is Daniel Augusto Bernal Jaramillo, identified as a director of Sofgen Pharma S.A. This status makes him an insider under SEC rules, requiring ongoing disclosure of future transactions in the company’s securities.

Does the Sofgen Pharma Form 3 show any insider buying or selling?

No, the Sofgen Pharma Form 3 shows no insider buying or selling activity. The transaction section is empty, and the summarized buy, sell, acquire, dispose, and exercise counts and share amounts are all reported as zero in this initial statement.

Are there any derivative securities reported in this Sofgen Pharma Form 3?

No derivative securities are reported in this Form 3 for Sofgen Pharma. The derivative summary is empty, and the derivative transaction count is zero, indicating no options, warrants, or similar instruments are disclosed for the reporting director.

Why is a Form 3 important for Sofgen Pharma insiders?

Form 3 is important because it establishes an insider’s baseline disclosure when they first become a reporting person. For Sofgen Pharma, this filing registers the director’s status and sets the starting point for any future Form 4 or Form 5 transaction reports.